/https://img.transistorcdn.com/DoORZz5tVXIWJlMOHSlRMpSQEs8SZDFF_jfvYPSj44w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xYzVi/MzRmNTc2ZjUzNmRk/MjU2YjQ1OTJjMzNl/MDE2Ny5qcGc.jpg)
Physician in the Loop: Speech-Language Pathology
Nomad Medical
Weekly Briefing for October 25 to 31, 2026
NOV 1, 20262 MIN
/https://img.transistorcdn.com/DoORZz5tVXIWJlMOHSlRMpSQEs8SZDFF_jfvYPSj44w/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8xYzVi/MzRmNTc2ZjUzNmRk/MjU2YjQ1OTJjMzNl/MDE2Ny5qcGc.jpg)
Description
The Food and Drug Administration (FDA) granted accelerated approval to Inovio Pharmaceuticals' Voceryq, a plasmid DNA immunotherapy, for adults with recurrent respiratory papillomatosis, based on fewer surgeries to remove airway growths. Paradromics said the FDA approved a protocol change that drops a four-hour travel limit for its study of an implanted brain-computer interface that translates intended speech.
Read this week's roundup and its sources: https://physicianintheloop.org/specialties/speech-language-pathology/2026-10-25/
Get this roundup by email, free
The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.

